Pyoderma gangrenosum in inflammatory bowel disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Pyoderma gangrenosum (PG) usually co-occurs with other diseases, most commonly inflammatory bowel disease (IBD), and is therefore a multidisciplinary problem. The review considers the relationship of diseases, the diagnosis of PG, topical and systemic therapy. PG often requires revision of IBD therapy. There are few randomized trials on the treatment of PG; the effectiveness of glucocorticosteroids, cyclosporine and tumor necrosis factor α inhibitors has been most proven. Reports of a positive effect of a number of biological agents and small molecules on PG make it possible to choose the therapy most indicated for the intestinal process.

Full Text

Restricted Access

About the authors

Andrey V. Yakubovsky

Pavlov University

Author for correspondence.
Email: ayakubovsky@mail.ru
ORCID iD: 0000-0003-0972-3363
SPIN-code: 1178-3234

Cand. Sci. (Med.), Associate Professor at the Department of Dermatovenereology with the Clinic

Russian Federation, St. Petersburg

E. V. Sokolovskiy

Pavlov University

Email: ayakubovsky@mail.ru
ORCID iD: 0000-0001-7610-6061
SPIN-code: 6807-7137

Department of Dermatovenereology with Clinic

Russian Federation, St. Petersburg

References

  1. George C., Deroide F., Rustin M. Pyoderma gangrenosum – a guide to diagnosis and management. Clin Med (Lond). 2019;19(3):224–28. doi: 10.7861/clinmedicine.19-3-224.
  2. Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А. и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10–44. doi: 10.33878/2073-7556-2023-22-1-10-44. [Shelygin Yu.A., Ivashkin V.T., Belousova E.A., et al. Ulcerative colitis (K51), adults. Koloproktolodiya. 2023;22(1):10–44. (In Russ.)].
  3. Ивашкин В.Т., Шелыгин Ю.А., Абдулгани- ева Д.И. и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8–38. [Crohn’s disease. Clinical recommendations (preliminary version). Koloproktolodiya. 2020;19(2):8–38. (In Russ.)].
  4. Harbord M., Annese V., Vavricka S.R., et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–54. doi: 10.1093/ecco-jcc/jjv213.
  5. Brocq L., Simon C. Contribution a l’etude du phagedenisme. Bull Soc Med Hop. Paris. 1908. P. 290–307.
  6. Brunsting L.A., Goeckerman W.H., O’Leary P.A. Pyoderma (ecthyma) gangrenosum. Arch Derm Syphilol. 1930;22(4):655–80. doi: 10.1001/archderm.1930.01440160053009.
  7. Langan S.M., Groves R.W., Card T.R., et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166–70. doi: 10.1038/jid.2012.130.
  8. Ashchyan H.J., Butler D.C., Nelson C.A., et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA. Dermatol. 2018;154(4):409–13. doi: 10.1001/jamadermatol.2017.5978.
  9. Yamamoto T. Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey. J Dermatol. 2019;46(4):e145–46. doi: 10.1111/1346-8138.14658.
  10. Monari P., Moro R., Motolese A., et al. Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study. Int Wound J. 2018;15(6):875–79. doi: 10.1111/iwj.12939.
  11. Hobbs M.M., Ortega-Loayza A.G. Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound J. 2020;17(5):1255–65. doi: 10.1111/iwj.13389.
  12. Maronese C.A., Pimentel M.A., Li M.M., et al. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615–34. doi: 10.1007/s40257-022-00699-8.
  13. Патрушев А.В., Самцов А.В., Барбинов В.В. и др. Гангренозная пиодермия: трудности в диагностике и терапии. Вестник дерматологии и венерологии. 2014;90(1):25–9. [Patrushev A.V., Samtsov A.V., Barbinov V.V., et al. Pyoderma gangrenosum: problems related to the diagnostics and treatment. Vestnik Dermatologii i Venerologii. 2014;90(1):25–9. (In Russ.)].
  14. Genovese G., Tavecchio S., Berti E., et al. Pyoderma gangrenosum-like ulcerations in granulomatosis with polyangiitis: two cases and literature review. Rheumatol Int. 2018;38(6):1139–51. doi: 10.1007/s00296-018-4035-z.
  15. Martinelli V.F., Martinelli B.P., Dantas de Oliveira L.S., et al. Atypical forms of pyoderma gangrenosum in inflammatory bowel disease: report of four cases and literature review. Int Med Case Rep J. 2022;15:449–56. doi: 10.2147/IMCRJ.S376915.
  16. Chen B., Li W., Qu B. Practical aspects of the diagnosis and management of pyderma gangrenosum Front Med. 2023;10:1134939. doi: 10.3389/fmed.2023.1134939.
  17. Bhat R.M. Pyoderma gangrenosum: an update. Indian Dermatol Online J. 2012;3(1):7–13. doi: 10.4103/2229-5178.93482.
  18. Maverakis E., Marzano A.V., Le S.T., et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81. doi: 10.1038/s41572-20-0213-x
  19. Falloon K., Cohen B., Ananthakrishnan A.N., et al. United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(9):1179–91. doi: 10.1111/apt.16853.
  20. Marzano A.V., Borghi A., Meroni P.L., et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br. J. Dermatol. 2016;175(5):882–91. doi: 10.1111/bjd.14691.
  21. Ruocco E., Sangiuliano S., Gravina A.G., et al. Pyoderma gangrenosum: an updated review. J. Eur. Acad. Dermatol. Venereol. 2009;23:1008. doi: 10.1111/j.1468-3083.2009.03199.x.
  22. Schosler L., Fogh K., Bech R. Pyoderma gangrenosum: a retrospective study of cliical characteristics, comorbidities, response to treatment and mortality related to prednisone dose. Acta. Derm. Venereol. 2021;101(4):adv00431. doi: 10.2340/00015555-3776.
  23. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000–5.
  24. Su W.P., Davis M.D., Weenig R.H., et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800. doi: 10.1111/j.1365-4632.2004.02128.x.
  25. Maverakis, E., Ma C., Shinkai, K., et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA. Dermatol. 2018;154(4):461–66. doi: 10.1001/jamadermatol.2017.5980.
  26. Hammer P., Latour E., Bohnett M., et al. The utility and challenges of histopathlogic evaluation in the diagnosis of nonmalignant skin ulcers. Wound Repair Regen. 2020;28:219–23. doi: 10.1111/wrr.12780.
  27. Jockenhofer F., Wollina U., Salva K.A., et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br. J. Dermatol. 2019;180(3):615–20. doi: 10.1111/bjd.16401.
  28. Адаскевич В.П. Гангренозная пиодермия: современное состояние проблемы. Consilium Medicum. 2021;23(8):603–8. [Adaskevich U.P. Pyoderma gangrenosum: current state of the problem. Consilium Medicum. 2021;23(8):603–8 (In Russ.)].
  29. Chen B., Li W., Qu B. Practical aspects of the diagnosis and management of pyderma gangrenosum Front. Med. 2023;10:1134939. doi: 10.3389/fmed.2023.1134939.
  30. Isene R., Bernklev T., Hoie O., et al. Extraintestinal manifestations in Crohn’s diease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand. J. Gastroenterol. 2014;50(3):300–5. doi: 10.3109/00365521.2014.99175.
  31. States V., O’Brien S., Rai J.P., et al. Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis. Dig. Dis. Sci. 2020;65(9):2675–85. doi: 10.1007/s10620-019-05999-4.
  32. Xu A., Strunk A., Garg A., et al. Prevalence of inflammatory bowel disease in patients with pyoderma gangrenosum: a population-based analysis. J. Am. Acad. Dermatol. 2022;86(6):1351–52. doi: 10.1016/j.jaad.2021.05.006.
  33. Langan S.M., Groves R.W., Card T.R., et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J. Invest. Dermatol. 2012;132:2166–70. doi: 10.1038/jid.2012.130.
  34. Ashchyan H.J., Butler D.C., Nelson C.A., et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA. Dermatol. 2018; 154(4):409–13. doi: 10.1001/jamadermatol.2017.5978.
  35. Yamamoto T., Yamasaki K., Yamanaka K., et al. Clinical guidance of pyoderma gagrenosum 2022. J Dermatol. 2023. doi: 10.1111/1346-8138.16845 (Online ahead of print).
  36. Weizman A.V., Huang B., Targan S., et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cutan Med Surg. 2014;18(5):361.
  37. Strunck J., Cutler B., Latour E., et al. Wound care dressings for pyoderma gangrenosum. J Am Acad Dermatol. 2022;86:458–60. doi: 10.1016/j.jaad.2021.09.053.
  38. Niu R., Zheng J., Ding D., et al. Giant pyoderma gangrenosum in a patient with ulcerative colitis: a case report. Medicine (Baltimore). 2020;99(6):e18795. doi: 10.1097/MD.0000000000018795.
  39. Chaby G., Viseux V., Poulain J.F., et al. Topical silver sulfadiazine-induced acute renal failure. Ann Dermatol Venereol. 2005;132(11 Pt. 1):891–93. doi: 10.1016/s0151-9638(05)79509-0.
  40. Ormerod A., Thomas K., Craig F., et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the stop gap randomised controlled trial. BMJ. 2015;350:h2958. doi: 10.1136/bmj.h2958.
  41. Landis E., Taheri A., Jorizzo J. Gulliver’s sign: a recognizable transition from inflammatory to healing stages of pyoderma gangrenosum. J Dermatol Treat. 2015;26:171–72. doi: 10.3109/09546634.2014.883061.
  42. Brooklyn T.N. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9. doi: 10.1136/gut.2005.074815.
  43. Garieri P., Marcasciano M., Greto Ciriaco A., et al. Pyoderma gangrenosum and inflammatory bowel disease: a combined medical and surgical approach - case report and literature review. Eur Rev Med Pharmacol Sci. 2022;26(14):5191–99. doi: 10.26355/eurrev_202207_29308.
  44. Partridge A.C.R., Bai J.W., Rosen C.F., et al. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol. 2018;179(2):290–95. doi: 10.1111/bjd.16485.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1. Pyoderma gangrenosum in a patient with Crohn's disease. Ulcerative form

Download (270KB)
Indexing metadata
3. Fig.2. Cribriform scar in a patient with Crohn's disease

Download (153KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies